NCT01998659View on ClinicalTrials.gov

Single Ascending Oral Dose Phase I Study With Px-102

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Healthy
Interventions
DRUG

Px-102

Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg

DRUG

Placebo

Oral drinking solution

Trial Locations (1)

Unknown

FOCUS Clinical Drug Development GmbH, Neuss

Sponsors
All Listed Sponsors
lead

Phenex Pharmaceuticals AG

INDUSTRY

NCT01998659 - Single Ascending Oral Dose Phase I Study With Px-102 | Biotech Hunter | Biotech Hunter